Skip to content
akaturk Academic measurement
Sign in Sign up

Article detail · 2024

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Journal The Lancet Neurology
ISSN1474-4422
YÖKSİS SJR Q1 JCR Q1
Year2024
Scopus (SJR)Q1
WoS (JCR)Q1
External linkhttps://doi.org/10.1016/ S1474-4422(24)00328-4

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueLANCET NEUROLOGY
  • Catalog match (ISSN)The Lancet Neurology

Abstract

Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.

Authors

22
  1. Xavier Montalban 1
  2. Patrick Vermesch 2
  3. Douglas Arnold 3
  4. Amit Bar-Or 4
  5. Bruce Cree 5
  6. Anne Cross 6
  7. Eva Kubala Havrdrova 7
  8. Ludwig Kappos 8
  9. Olaf Stuve 9
  10. Heinz Weindl 10
  11. Jerry Wolinsky 11
  12. Frank Dahlke 12
  13. Claire Le Bolay 13
  14. Li Shen Loo 14
  15. Sathej Gopalakrishnan 15
  16. Yann Hyvert 16
  17. Andrija Javor 17
  18. Hans Guehring 18
  19. Nadia Tenenbaum 19
  20. Davorka Tomic 20
  21. EvolutionRMS Investigators 21
  22. KADRİYE AĞAN YILDIRIM MARMARA ÜNİVERSİTESİ 22